Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Benzinga Newsdesk www.benzinga.com Positive 85.4%

Neg 0% Neu 0% Pos 85.4%

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.